A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting Treatment

July 24, 2015

By Shivani Tripathi, MD
Milan J. Anadkat, MD

Poll

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. According to the image below, which medication is most likely responsible?

Image courtesy of Shivani V. Tripathi, M.D. and Milan J. Anadkat, M.D.

What is your diagnosis?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.

Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.

Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.

Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.

At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.

Related Content

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Neil M. Iyengar, MD

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

Related Content

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Neil M. Iyengar, MD

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Maximizing Safe Resection in High-Grade Gliomas

Maximizing Safe Resection in High-Grade Gliomas

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.